Induction chemotherapy is likely to be effective for biologically distinct subgroups of cancer patients with biomarker detection. In order to investigate the prognostic and predictive values of cyclin D1 expression in patients with oral squamous cell carcinoma(OSCC) who were treated in a prospective, expression could be used as a biomarker in further validation studies to select cN2 patients that could benefit from induction therapy.
4
cN2 OSCC patients with high cyclin D1 expression can benefit from the addition of TPF induction chemotherapy to standard treatment. Cyclin D1 expression could be used as a biomarker in further validation studies to select cN2 patients that could benefit from induction therapy.
Introduction
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor in the oral and maxillofacial region, with about 300,000 new cases worldwide each year (1, 2) . Many efforts have been made to improve the diagnosis and treatment of OSCC patients; however, the prognosis is still poor with a 5-year survival rate of approximately 50-60% (3, 4) , with even poorer outcomes noted in those patients with local-regionally advanced disease. For patients with resectable locally advanced OSCC, the most commonly recommended treatment is radical surgery followed by post-operative radiotherapy or chemoradiotherapy depending on the presence of high risk features in the surgical specimen.
Induction chemotherapy has been investigated as a possible strategy to shrink or downstage locally advanced head and neck cancers, increase organ preservation rates, and/or reduce the risk of locoregional and/or distant recurrence, ultimately improving treatment outcomes. Induction chemotherapy with a combination of docetaxel, cisplatin and 5-fluorouracil (TPF) followed by radiotherapy or chemoradiotherapy has been shown to improve overall survival (OS) compared to induction chemotherapy with cisplatin and 5-fluorouracil (PF) in two randomized phase 3 trials (TAX323 and TAX324) (5-7). As a result, TPF is suggested as the preferred combination chemotherapy regimen when induction treatment is used for non-surgical Despite the potential benefits seen in these initial studies, the role of TPF induction chemotherapy for non-surgical management of head and neck squamous cell carcinomas has been questioned especially after presentation of the results of the recently completed DeCIDE and PARADIGM trials. These studies compared chemoradiotherapy upfront versus induction TPF followed by chemoradiotherapy, and failed to demonstrate a significant improvement in OS or disease-free survival (DFS) for patients receiving TPF (8, 9 ).
To address the role of induction TPF in HNSCC treated with surgery (as opposed to the non-surgical approach utilized in the aforementioned studies),
we recently conducted and presented the results of a randomized, phase 3 trial of induction TPF followed by surgical resection versus surgical resection upfront in patients with locally advanced OSCC (10). In concert with DeCIDE and PARADIGM, we were also unable to demonstrate a survival advantage for induction chemotherapy in the overall study population. Taken together, these data demonstrate that induction chemotherapy should not be universally integrated into non-surgical or surgical management of patients with OSCC. It is possible, however, that induction chemotherapy with TPF might improve outcomes in molecularly defined subgroups of patients, and correlative studies from the aforementioned randomized trials could assist in identifying candidate biomarkers predictive of benefit from induction treatment.
The cyclin D1 gene is a proto-oncogene located on chromosome 11q13, which encodes the cyclin D1 nuclear protein, a positive cell cycle regulator.
Cyclin D1 binds and activates CDK4 and CDK6, forming a complex that catalyzes Rb protein phosphorylation resulting in the release of transcriptional regulators E2F from Rb. This promotes cell cycle progression from G1 to S phase (11). Although increased expression of cyclin D1 in OSCC has been reported, there are controversial data on the prognostic value of cyclin D1 overexpression in OSCC. Some studies suggest that increased expression of cyclin D1 is associated with poor survival (12) (13) (14) (15) (16) , while other studies demonstrate that cyclin D1 overexpression provides little prognostic information for patients with OSCC (17, 18) .
The aim of this study is to evaluate cyclin D1 expression in the pretreatment biopsy samples from patients who had local-regionally advanced, resectable OSCC and had been enrolled in a randomized phase 3 trial of TPF induction chemotherapy followed by surgery and post-operative radiotherapy compared to upfront surgery and post-operative radiotherapy, and to examine its possible prognostic and predictive role in this patient population. We hypothesize that high levels of expression of cyclin D1 will be associated with shortened OS in patients treated with surgery upfront, but will be predictive of OS benefit from TPF induction chemotherapy. After treatment, patients were monitored every three months in the first two years, every six months in the subsequent 3-5 years, and once a year thereafter until death or data censoring.
Detection of cyclin D1 expression using immunohistochemistry
Pretreatment formalin fixed and paraffin embedded biopsy samples were collected for detection of cyclin D1 expression; however, in the control arm, if pretreatment biopsy was unavailable, a portion of the surgical resection and weak positive cyclin D1 expression, whereas high cyclin D1 expression was defined as strong positive cyclin D1 expression. This was based on previous studies demonstrating that the chosen cutoff of 50% was reasonable for prognostic analysis in OSCC (12,24).
Statistical analysis
Overall survival (OS) was calculated from the date of randomization to the date of death; disease-free survival (DFS) /locoregional recurrence-free survival (LRFS) /distant metastasis-free survival (DMFS) were calculated, respectively, from the date of randomization to recurrence/locoregional recurrence/distant metastasis or death from any cause. 
Results

Patient characteristics and treatment outcomes
From 03/2008 to 12/2010, 256 eligible patients were enrolled in this study (128 patients in each arm), and 232 (91%, 127 patients in the control arm, 105 patients in the experimental arm) patients were assessed for pretreatment cyclin D1 expression levels in the tumor. The distribution of baseline characteristics in the subset of patients that had biomarker evaluation was similar to the distribution in the entire trial population (Table 1) . No patients were lost to follow-up. The median follow-up time was 30 months among the censored patients.
As previously described, no significant differences in OS, DFS, LRFS, or DMFS could be identified between the experimental and control arms in the entire patient population 10 . On exploratory analysis, cN2 patients benefited from TPF induction chemotherapy as regards to OS and DMFS 10 . The same analysis was performed in the 232 patients who had baseline cyclin D1 levels evaluated (Supplemental Figure S2) . In this subset, OS at 2 years for the control and experimental arms was 68.8% and 72.6%, respectively (P=0.472).
Disease-free survival at 2 years was 64.5% and 66.0%, respectively (P=0.592).
The locoregional recurrence rate and distant metastasis rate in the control arm were 30.5% and 8.7%, respectively; in the experimental arm, the locoregional recurrence rate and distant metastasis rate were 31.3% and 5.5%, respectively. As observed for the entire trial population, cN2 patients benefited from TPF induction chemotherapy as regards to OS and DMFS (Supplemental Table   S1 ).
Cyclin D1 expression and baseline characteristics (Table 1) .
Cyclin D1 expression and patients' outcomes
In the control arm, a low cyclin D1 expression predicted better outcomes with regard to OS, DFS, LRFS and DMFS (Figure 2 
respectively (HR=0.571, 95% CI 0.321-1.006, P=0.053). The locoregional recurrence rate was 25.2% and 40.3% in the patients with low and high cyclin D1 expression, respectively; the distant metastasis rate was 5.2% and 9.1% in the patients with low and high cyclin D1 expression, respectively. The same association between high cyclin D1 expression levels and poor treatment outcomes (including OS, DFS, LRFS, and DMFS) were observed in patients treated with induction TPF (Figure 3) , and in patients when putting the two arms together (Supplemental Figure S3) . Exploratory subgroup analysis was Table S2 
including cyclin D1 expression and lymph node status (clinical stage was not included because of the overlap between lymph node status and clinical stage) in the control arm, cyclin D1 expression and clinical stage in the experimental arm. Cyclin D1 expression was found to be an independent risk factor for prognosis (Supplemental Table S3 ). Taken together, these data demonstrate that high level of expression of cyclin D1 is a poor prognostic biomarker in patients with OSCC. To assess whether cyclin D1 expression could serve as a predictive biomarker of benefit from induction chemotherapy, we analyzed the interaction between the biomarker, treatment and survival outcomes. There were no significant differences in outcome between the experimental and control arms in patients with low cyclin D1 expression or in patients with high cyclin D1 expression ( Table 2) .
As previously described, both high cyclin D1 expression and cN2 were found to be associated with a higher risk for distant metastasis and reduced OS. We also demonstrated that TPF improves OS and DMFS in the cN2 subgroup. To assess whether cyclin D1 expression could serve as a predictive biomarker of benefit from TPF in a subset of patients at high risk for distant metastases and death, we performed an exploratory analysis of the interaction between cyclin D1, cN2 and survival outcomes. cN2 patients with high cyclin D1 expression benefited from TPF induction chemotherapy with respect to OS (HR=5.888, 95% CI 1.097-31.613, P=0.025) and DMFS (HR=5.888, 95% CI 1.097-31.613, P=0.025), while the cN2 patients with low cyclin D1 expression did not benefit from TPF induction chemotherapy (Figure 4 , Supplemental Table S5 ). In contrast, the cN0 and cN1 patients, with either low or high cyclin D1 expression, did not benefit from TPF induction chemotherapy with regard to OS, DFS, LRFS and DMFS (Supplemental Table S5 ). There was no clear benefit from induction chemotherapy in any other subgroups (data not shown). 
Discussion
In this study, we found that lower cyclin D1 expression in the pretreatment biopsy samples was a favorable prognostic biomarker, as it was associated with better OS, DFS, LRFS and DMFS in patients with resectable locally advanced OSCC treated in a prospective, randomized, phase 3 trial. Cyclin D1 expression was not a predictive biomarker of benefit from induction TPF in the population overall. However, on exploratory analysis, patients with cN2 nodal staging and high cyclin D1 expression benefited from TPF induction chemotherapy in terms of OS and DMFS; while cN2 patients with low cyclin D1 expression did not derive benefit from induction treatment. A limitation of our study, however, includes the fact that only 47 cN2 patients were assessed for cyclin D1 expression in the pretreatment biopsy samples. As such, these results need to be considered exploratory and hypothesis generating, and clearly need to be confirmed in further clinical trials with larger sample sizes. 
In addition to our findings related to cyclin D1 expression, other biomarkers have been evaluated as potential predictors of benefit from induction treatment by other groups: p53 gene mutations have been found to be strongly associated with lower response rates to PF induction chemotherapy (34, 35) ; Beta-tubulin and Bcl-xl (36-38) have also been found to be prognostic and predictive biomarkers in HNSCC patients receiving induction TPF or PF. However, before being widely embraced, further clinical trials using cyclin D1 and other prognostic and/or predictive biomarkers are needed to validate their clinical utility, and to realize the goal of personalized treatment of HNSCC patients based on their biomarker blueprint.
In conclusion, our study suggests that cyclin D1 high expression level should be considered a prognostic biomarker of poor outcomes in patients with resectable locally advanced OSCC, and as a possible predictive biomarker of benefit from TPF induction chemotherapy in patients with cN2 disease. Based on these findings, we plan to launch a randomized study of induction TPF in patients with cN2 OSCC, prospectively embedding cyclin D1 expression as a predictive biomarker in the clinical trial design. This will hopefully contribute to the development of a personalized induction treatment strategy for HNSCC. 2) 43 (55.8) *P value from the chi-square test was reported to compare the difference between low and high cyclin D1 expression based on the different baseline factors. **Former/current smokers defined as at least a one pack-year history of smoking. ***Positive alcohol use was defined as current alcohol use of more than one drink per day for 1 year (12 ounces of beer with 5% alcohol, or 5 ounces of wine with 12%-15% alcohol, or one ounce of liquor with 45%-60% alcohol). All other patients were classified as negative alcohol use. 
